Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
Accession Number
Approved, Experimental

Belladonna, also known as atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family Solanaceae. Its roots, leaves and fruits contain Hyoscyamine, Scopolamine, and mostly, Atropine. These alkaloids are naturally-occurring muscarinic antagonists. Atropine is a non-selective muscarinic antagonist that is mainly used as an adjunct for anaesthesia. The name "belladonna" originates from the Italian words "beautiful woman" and the historical use of herb eye-drops by women to dilate the pupils of the eyes for aesthetic purposes. Belladonna is a poisonous plant and belladonna intoxication from accidental ingestion may result in a severe anticholinergic syndrome, which is associated with both central and peripheral manifestations 1.

  • Atropa belladona
  • Atropa belladonna
  • Deadly nightshade
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Belladone TctTinctureOralLaboratoire Atlas Inc1951-12-312006-06-14Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Bellergal SpacetabsBelladonna (0.2 mg) + Ergotamine tartrate (0.6 mg) + Phenobarbital (40.0 mg)Tablet, extended releaseOralPaladin Labs Inc1959-01-012018-06-05Canada
Bellergal TabBelladonna (.1 mg) + Ergotamine (.3 mg) + Phenobarbital (20 mg)TabletOralSandoz1951-12-311997-08-12Canada
Cafergot Pb SupBelladonna (0.25 mg) + Caffeine (100 mg) + Ergotamine (2 mg) + Pentobarbital (60 mg)SuppositoryRectalNovartis1958-12-312003-01-15Canada
Cafergot Pb TabBelladonna (0.125 mg) + Caffeine (100 mg) + Ergotamine (1 mg) + Pentobarbital Sodium (30 mg)TabletOralNovartis1951-12-311999-08-04Canada
Hemorro-dol SupBelladonna (11.25 mg) + Balsam of Peru (22.6 mg) + Benzocaine (50 mg) + Bismuth subcarbonate (86.4 mg) + Bismuth subnitrate (37.8 mg) + Boric acid (226.7 mg) + Ephedrine sulfate (2.5 mg) + Zinc oxide (226.7 mg)SuppositoryRectalProduits Francais Labs Inc.1981-12-311997-05-30Canada
Opium and Belladonna SupBelladonna (15 mg) + Opium (65 mg)SuppositoryRectalSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-311998-07-28Canada
PMS-opium and Belladona SupBelladonna (15 mg) + Opium (65 mg)SuppositoryRectalPharmascience Inc1991-12-312016-10-28Canada
Robol TabBelladonna (5.4 mg) + Alloin (16.2 mg) + Ipecac (4.32 mg) + Phenolphthalein (64.8 mg)TabletOralLabs Anglo French1979-12-311997-08-05Canada
Sandoz Opium & BelladonnaBelladonna (15 mg) + Opium (65 mg)SuppositoryRectalSandoz Canada Incorporated1991-12-31Not applicableCanada
Wigraine SuppositoriesBelladonna (.1 mg) + Caffeine (100 mg) + Ergotamine tartrate (1 mg)SuppositoryRectalOrganon Canada Ltd Ltee1981-12-311997-08-18Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Belladonna and OpiumBelladonna (16.2 mg/1) + Opium (30 mg/1)SuppositoryRectalPaddock Laboratories, LLC1994-05-01Not applicableUs
Belladonna and OpiumBelladonna (16.2 mg/1) + Opium (60 mg/1)SuppositoryRectalPaddock Laboratories, LLC1997-04-22Not applicableUs
CAS number
Not Available



No therapeutic indications.

Associated Conditions

The active components of belladonna mediate anticholinergic actions. The main effects include inhibition of secretions such as dry mouth, tachycardia, pupillary dilation and paralysis of accommodation, relaxation of smooth muscles in the gut, bronchi, biliary tract and bladder (urinary retention), and inhibition of gastric acid secretion 3. Atropine is a stimulant of the central nervous system 3.

Mechanism of action

The active components of belladonna act as competitive antagonists at muscarinic receptors and block the binding of acetylcholine to the central nervous system and parasympathetic postganglionic muscarinic receptors 1.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

For pharmacokinetic information of the active ingredients, refer to Atropine, Hyoscyamine, or Scopolamine.

Volume of distribution

For pharmacokinetic information of the active ingredients, refer to Atropine, Hyoscyamine, or Scopolamine.

Protein binding

For pharmacokinetic information of the active ingredients, refer to Atropine, Hyoscyamine, or Scopolamine.


For pharmacokinetic information of the active ingredients, refer to Atropine, Hyoscyamine, or Scopolamine.

Route of elimination

For pharmacokinetic information of the active ingredients, refer to Atropine, Hyoscyamine, or Scopolamine.

Half life

For pharmacokinetic information of the active ingredients, refer to Atropine, Hyoscyamine, or Scopolamine.


For pharmacokinetic information of the active ingredients, refer to Atropine, Hyoscyamine, or Scopolamine.


Oral LD50 of atropine is 75 mg/kg in mouse. Clinical manifestations of anticholinergic syndrome include both central and peripheral effects. Central symptoms, which are dose-dependent and anticholinergic agent-specific, include ataxia, disorientation, short-term memory loss, confusion, hallucinations, psychosis, agitated delirium, seizures, coma, respiratory failure or cardiovascular collapse 1. Peripheral effects include mydriasis with cycloplegia, dry mucous membranes, hyperreflexia, flushed skin, diminished bowel sounds or ileus, urinary retention, tachycardia, and hypertension or hypotension 1. Management of anticholinergic intoxication should be symptomatic including gastrointestinal decontamination with activated charcoal 1. The antidote for belladonna poisoning is Physostigmine, which is the same as for atropine 1. Physosigmine crosses the blood-brain barrier and reversibly inhibits anticholinesterase. Benzodiazepines are frequently used for sedation to control anticholinergic effects including delirium and agitation 2.

Affected organisms
Not Available
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available


General References
  1. Berdai MA, Labib S, Chetouani K, Harandou M: Atropa belladonna intoxication: a case report. Pan Afr Med J. 2012;11:72. Epub 2012 Apr 17. [PubMed:22655106]
  2. Demirhan A, Tekelioglu UY, Yildiz I, Korkmaz T, Bilgi M, Akkaya A, Kocoglu H: Anticholinergic Toxic Syndrome Caused by Atropa Belladonna Fruit (Deadly Nightshade): A Case Report. Turk J Anaesthesiol Reanim. 2013 Dec;41(6):226-8. doi: 10.5152/TJAR.2013.43. Epub 2013 May 23. [PubMed:27366377]
  3. 13. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 159-161). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
External Links
AHFS Codes
  • 12:08.08 — Antimuscarinics Antispasmodics

Clinical Trials

Clinical Trials
3RecruitingTreatmentBreast Cancer1
4CompletedPreventionPainful Bladder Syndrome (PBS) / Urinary Bladder, Neurogenic / Urinary Bladder, Overactive / Urinary Urge Incontinence1
4CompletedTreatmentCalcium Nephrolithiasis1
4CompletedTreatmentHysterectomy / Postoperative pain1
4CompletedTreatmentVaginal Surgery1
4RecruitingTreatmentUrinary Tract Infection1
4TerminatedTreatmentUrinary Bladder, Overactive1
Not AvailableCompletedSupportive CareElective Cystoscopy / General Surgery / Ureteroscopy1
Not AvailableCompletedTreatmentPain / Pain Management1


Not Available
Not Available
Dosage forms
Tablet, extended releaseOral
Not Available
Not Available


Experimental Properties
Not Available


Not classified

Drug created on September 22, 2017 14:50 / Updated on February 25, 2020 00:21